## **Product** Data Sheet

# Ondansetron-d<sub>5</sub>

 Cat. No.:
 HY-B0002BS

 CAS No.:
 1219798-86-3

 Molecular Formula:
 C<sub>18</sub>H<sub>14</sub>D<sub>5</sub>N<sub>3</sub>O

Molecular Weight: 298.39

Target: 5-HT Receptor

Pathway: GPCR/G Protein; Neuronal Signaling

Storage: Powder -20°C

4°C 2 years

3 years

In solvent -80°C 6 months

-20°C 1 month

#### **SOLVENT & SOLUBILITY**

In Vitro

DMSO: 10 mg/mL (33.51 mM; Need ultrasonic)

Preparing Stock Solutions	Solvent Mass Concentration	1 mg	5 mg	10 mg
	1 mM	3.3513 mL	16.7566 mL	33.5132 mL
	5 mM	0.6703 mL	3.3513 mL	6.7026 mL
	10 mM	0.3351 mL	1.6757 mL	3.3513 mL

Please refer to the solubility information to select the appropriate solvent.

### **BIOLOGICAL ACTIVITY**

Description	Ondansetron- $d_5$ is the deuterium labeled Ondansetron. Ondansetron (GR 38032; SN 307) is a serotonin 5-HT3 receptor antagonist used mainly as anantiemetic (to treat nausea and vomiting), often following chemotherapy.
In Vitro	Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs <sup>[1]</sup> .  MCE has not independently confirmed the accuracy of these methods. They are for reference only.

#### **REFERENCES**

- [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216.
- $[2]. Brown AM, et al. Ion permeation and conduction in a human recombinant 5-HT3 receptor subunit (h5-HT3A). \\ J Physiol. 1998 Mar 15;507 (Pt 3):653-65. \\ In the permeation and conduction in a human recombinant 5-HT3 receptor subunit (h5-HT3A). \\ J Physiol. 1998 Mar 15;507 (Pt 3):653-65. \\ In the permeation and conduction in a human recombinant 5-HT3 receptor subunit (h5-HT3A). \\ J Physiol. 1998 Mar 15;507 (Pt 3):653-65. \\ In the permeation and conduction in a human recombinant 5-HT3 receptor subunit (h5-HT3A). \\ J Physiol. 1998 Mar 15;507 (Pt 3):653-65. \\ In the permeation and conduction in a human recombinant 5-HT3 receptor subunit (h5-HT3A). \\ J Physiol. 1998 Mar 15;507 (Pt 3):653-65. \\ J Physiol. 1998 Mar 15;507 (Pt 3):653-65. \\ J Physiol. 2008 Mar 15;50$
- [3]. Barann M, et al. Recombinant human 5-HT3A receptors in outside-out patches of HEK 293 cells: basic properties and barbiturate effects. Naunyn Schmiedebergs Arch

Pharmacol. 2000 Sep;362(3):255-65.

- [4]. Wildeboer KM, et al. Ondansetron results in improved auditory gating in DBA/2 mice through a cholinergic mechanism. Brain Res. 2009 Dec 1;1300:41-50.
- [5]. Khedhaier A, et al. Circadian rhythms in toxic effects of the serotonin antagonist ondansetron in mice. Chronobiol Int. 2003 Nov;20(6):1103-16.
- [6]. Umathe SN, et al. The 5-HT3 receptor antagonist, ondansetron, blocks the development and expression of ethanol-induced locomotor sensitization in mice. Behav Pharmacol. 2009 Feb;20(1):78-83.
- [7]. Doggrell SA, et al. Cardiac safety concerns for ondansetron, an antiemetic commonly used for nausea linked to cancer treatment and following anaesthesia. Expert Opin Drug Saf. 2013 May;12(3):421-31.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA